Anika Therapeutics, Inc. (ANIK)
14.96
+0.05
(+0.34%)
USD |
NASDAQ |
May 18, 14:42
Anika Therapeutics Research and Development Expense (Quarterly) : 6.713M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BioCryst Pharmaceuticals, Inc. | 59.26M |
| Elutia, Inc. | 1.973M |
| Plus Therapeutics, Inc. | 2.865M |
| Perspective Therapeutics, Inc. | 20.25M |
| AVITA Medical, Inc. | 5.629M |